Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical trial of CEN501 a nasal strip product used as a local nasal immunotherapy (LNIT) for the treatment of mite-induced allergic rhinitis patients

Next Previous
Trial Profile

A phase I clinical trial of CEN501 a nasal strip product used as a local nasal immunotherapy (LNIT) for the treatment of mite-induced allergic rhinitis patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CEN 501 (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions

Most Recent Events

  • 10 May 2022 New trial record
  • 03 May 2022 According to an ABVC Biopharma media release, the BioKey, a wholly-owned subsidiary of the company entered into a $3.0 million clinical services contract with NeuCen BioMed Co. Ltd. to guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under U.S. FDA IND regulatory requirements.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top